Focal segmental glomerulosclerosis: Cellular variant and beyond  by Nair, R.
1676   Kidney International (2006) 70
commentar y
function and localization have remained 
normal. In the control and ENaC-defi cient 
mice, furosemide induced normal urinary 
acidifi cation with a similar increase in frac-
tional electrolyte excretion.7 Th erefore it 
appears that the residual ENaC function in 
the CNT may be adequate for the furosem-
ide-dependent urinary acidifi cation. Th ese 
data demonstrate that the CNT is the major 
segment in electrogenic urinary acidifi ca-
tion, thus reinforcing the central role of the 
CNT in overall electrolyte transport.
REFERENCES
1. Biner HL, Arpin-Bott MP, Loffing J et al. Human 
cortical distal nephron: distribution of electrolyte 
and water transport pathways. J Am Soc Nephrol 
2002; 13: 836–847.
2. Loffing J, Kaissling B. Sodium and calcium transport 
pathways along the mammalian distal nephron: 
from rabbit to human. Am J Physiol Renal Physiol 
2003; 284: F628–F643.
3. Loffing J, Loffing-Cueni D, Valderrabano V et al. 
Distribution of transcellular calcium and sodium 
transport pathways along mouse distal nephron. 
Am J Physiol Renal Physiol 2001; 281: F1021–F1027.
4. Ellison DH, Velàzques H, Wright FS. Adaptation of 
the distal convoluted tubule of the rat. J Clin Invest 
1989; 83: 113–126.
5. Muto S. Potassium transport in the mammalian 
collecting duct. Physiol Rev 2001; 81: 85–116.
6. Meneton P, Loffing J, Warnock DG. Sodium and 
potassium handling by the aldosterone-sensitive 
distal nephron: the pivotal role of the distal and 
connecting tubule. Am J Physiol Renal Physiol 2004; 
287: F593–F601.
7. Kovacikova J, Winter C, Loffing-Cueni D et al. 
The connecting tubule is the main site of the 
furosemide-induced urinary acidification by the 
vacuolar H+-ATPase. Kidney Int 2006; 70: 1706–1716. 
8. Capasso G, Malnic G, Wang T, Giebisch G. 
Acidification in mammalian cortical distal tubule. 
Kidney Int 1994; 45: 1543–1554.
9. Wagner CA, Finberg KE, Breton S et al. Renal vacuolar 
H+-ATPase. Physiol Rev 2004; 84: 1263–1314.
10. Rubera I, Loffing J, Palmer LG et al. Collecting duct–
specific gene inactivation of αENaC in the mouse 
kidney does not impair sodium and potassium 
balance.  J Clin Invest 2003; 112: 554–565.
see original article on page 1783
Focal segmental 
glomerulosclerosis: Cellular variant 
and beyond
R Nair1
The entity of focal segmental glomerulosclerosis (FSGS), oddly, includes 
several distinct changes involving glomeruli that need not be focal, 
segmental, or even sclerotic. It is fitting to rethink our nosological 
approach to FSGS, which has focused on descriptive morphological 
entities. Rather, we should consider them as ‘podocytopathies’ — diseases 
with an etiological commonality involving injury to the podocyte.
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Primary focal segmental glomerulosclero-
sis (FSGS) represents a group of diseases 
that present with nephrotic syndrome or 
nephrotic-range proteinuria and are char-
acterized by varied glomerular morpho-
logical changes. 
Th e fi ve variants of FSGS as proposed 
in the Columbia Classifi cation of 2004 are 
listed in Table 1. Several causes of FSGS, 
both genetic and acquired, have been 
reported in the past decade,1 and new 
ones are being discovered. Even though 
the glomerular lesions of FSGS may not 
be focal, segmental, or sclerotic, they have 
a common anatomic injury involving the 
glomerular epithelial cell, oft en referred to 
as podocytopathy. Variants of FSGS such 
as cellular (CELL), collapsing (COLL), and 
glomerular tip lesion (GTL) have been his-
torically designated as FSGS, as they oft en 
have coexisting segmental sclerotic lesions 
of the classic (not otherwise specified 
(NOS)) type and have nephrotic-range 
proteinuria. However, collective inclusion 
under the banner of FSGS may not be as 
appropriate as it may seem. For example, 
GTL may be more appropriately consid-
ered a form of minimal-change disease 
rather than of FSGS, given the excellent 
response to treatment in many instances.2 
To quote Martin Pollack, “Too oft en, we 
talk about histologic patterns of injury, 
such as focal and segmental glomerulo-
sclerosis, as if they were diseases rather 
than descriptions of kidney biopsy speci-
mens at particular points in time.”3 An 
alternative approach to understanding and 
classifying the variants of primary FSGS 
is to consider them as ‘podocytopathies’ 
(Table 1). Such a categorization might well 
also include minimal-change disease4 but 
exclude the perihilar FSGS variant, for 
reasons discussed shortly. Th is may be a 
more elegant approach that would refer to 
a disease process rather than a nonspecifi c 
pathological fi nding.
It has to be emphasized that segmen-
tal sclerotic lesions can simply represent 
glomerular scars and can be seen in a 
myriad of conditions, such as chronic cres-
centic glomerulonephritis and chronic IgA 
nephropathy, Alport’s syndrome, Fabry’s 
disease, and so on — the so-called ‘fi nal 
common pathway’. In this sense, FSGS can 
be considered as a fi nal histopathological 
end point to varying biological mecha-
nisms.5 Every eff ort should be made to rule 
out a secondary (non-podocytopathic) 
cause for FSGS. Th is can prove to be quite 
diffi  cult when the sequential clinical events 
over the period of time the patient was fol-
lowed are not known. Th e clinician should 
beware the purely pathological diagnosis 
of FSGS — not otherwise specifi ed. Th e 
term ‘FSGS’ can be misleading and per-
haps should be used only as a descriptive 
morphological term.
It is in this context that a concerted 
attempt to defi ne the various glomeru-
lar lesions that fall under the collective 
umbrella of the term ‘FSGS’ was made by a 
group of leading renal pathologists in what 
is popularly referred to as the Columbia 
Classifi cation.6 Although there are some 
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problems with this classifi cation, the dis-
cussion of which is beyond the scope of 
this Commentary, it remains the most 
comprehensive attempt at tackling a dif-
fi cult subject. One of the important results 
was to establish clear criteria distinguish-
ing between the collapsing and cellular 
variants of FSGS. Before this paper, the two 
terms had oft en been used interchangeably 
or synonymously, leading to considerable 
diagnostic confusion.
Now CELL has been introduced as a 
distinct entity. It is evident that this is the 
rarest of the variants of FSGS, and con-
sequently the least understood.7 Stokes et 
al.8 (this issue) have now made the fi rst 
attempt to study specifi cally the cellular 
lesion and its implications in comparison 
with other variants. Th ey compared four 
of the fi ve variants of FSGS, excluding the 
perihilar variant, which generally is con-
sidered a secondary form of FSGS, indica-
tive of adaptive responses consequent to 
nephron loss or glomerular hypertension.6 
CELL emerges as a variant of FSGS with 
a specifi c prognostic signifi cance (time to 
end-stage disease, treatment response) 
intermediate between those of COLL and 
GTL. Th e prognostic diff erences between 
CELL and NOS are less evident. Th e study 
confi rms the value in distinguishing CELL 
as a separate subset under the umbrella 
of FSGS.
Adequate sampling and sectioning is 
emphasized in rendering a pathological 
diagnosis of CELL and other forms of 
FSGS. Deeper sectioning of the biopsy 
tissue in the study by Stokes et al.8 led to 
reclassifi cation of CELL as GTL in up to 
30% of cases and can also lead to reclas-
sifi cation as COLL or even the perihilar 
variant. It is interesting to note that the 
same authors had previously forwarded 
the hypothesis that CELL may represent 
a more advanced form of GTL. It is also to 
be understood that the defi nition of CELL 
as typical expansile lesions involving 25% 
or more6 of the glomerular tuft  is arbitrary. 
All these considerations underscore the 
importance of adequate sampling to rule 
out the presence of exclusionary lesions 
such as GTL and COLL. Put in a diff erent 
way, the diagnosis of CELL does not rule 
out other variants of FSGS. Several issues 
concerning CELL need to be addressed in 
the future. What does the presence of intra-
capillary foam cells mean? Are they just 
indicative of heavy proteinuria, as has been 
proposed with GTL?9 Do these lesions 
regress without segmental scarring? Are 
there any specifi c diseases associated with 
CELL, such as the association of COLL 
with human immunodeficiency virus, 
pamidronate toxicity, and so on?
Th e limitations on rendering an accu-
rate diagnosis of FSGS due to sampling 
bias, inability to decide confidently 
whether the etiology is primary or sec-
ondary by pathology alone, and the 
diffi  culty in predicting treatment response 
by morphology alone have led to a 
certain degree of angst among nephrolo-
gists toward the patholo–gical diagnosis 
of FSGS. In many instances the decision 
whether or not to treat with immunosup-
pression still remains a clinical decision 
heavily tempered by the individual phi-
losophy of the nephrologist. Th e general 
wisdom is that if nephrotic proteinuria is 
present, and if chronic changes are mild 
to moderate, then one should treat with 
steroids. Th e best indicator of prognosis 
is initial response to treatment.10
Attempts to solve the problem of non-
predictive morphological features of 
FSGS are rather disjointed, and informa-
tion seems to be trickling in from various 
centers. It is time to gather forces to tackle 
this issue. One such eff ort, the Focal and 
Segmental Glomerulosclerosis (FSGS) 
Clinical Trial sponsored by the National 
Institutes of Health/National Institute of 
Diabetes and Digestive and Kidney Dis-
eases, is currently under way, under the 
leadership of the Columbia group. Th is 
is a multicenter prospective randomized 
trial of treatment of steroid-resistant 
focal and segmental glomerulosclerosis. 
More can be done. Th e real answer that 
the nephrologist wants from a biopsy 
is whether to treat with steroids or not. 
Th e eff orts to answer this question have 
been yielding results. A highly simplifi ed 
approach toward therapeutic interven-
tion based purely on pathology with the 
use of currently available data is given in 
Table 2.
It is quite possible that in the not too dis-
tant future, with the concerted attempts of 
nephrologists, pathologists, researchers in 
the fi eld, and the use of exciting new meth-
ods such as genomics and proteomics, and 
with new therapeutic modalities, we will 
be able to solve the riddle of primary FSGS 
(or is it primary podocytopathy?).
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Table 1 | Current morphological vs. tentative etiological classification of FSGS
The Columbia Classification of primary FSGS in adults Primary podocytopathies
FSGS, not otherwise specified (NOS) Minimal-change disease?
FSGS, glomerular tip lesion (GTL) FSGS, glomerular tip lesion 
FSGS, cellular (CELL) FSGS, cellular
FSGS, collapsing (COLL) FSGS, collapsing 
FSGS, perihilar (PH) FSGS, not otherwise specified
FSGS, focal segmental glomerulosclerosis.
Table 2 | An approach to treatment of primary focal segmental glomerulosclerosisa 





Cellular (CELL) Collapsing (COLL) Perihilar (PH)
Treatb only if 
nephrotic









aAll attempts to rule out a secondary cause should be made. The biopsy findings should only show mild to early-
moderate chronic changes. b Treat with high-dose steroids.
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Adiponectin versus angiotensin 
II: Key pathological role of their 
misbalance
H Suzuki1,2 and S Eguchi1,2
Kurata et al. report that an angiotensin II type-1 receptor blocker 
(ARB) inhibits obesity-induced hypoadiponectinemia in rats through 
inhibition of reactive oxygen species generation. Taken together with 
the recently reported functional interplay between adiponectin and 
angiotensin II, this suggests that adiponectin probably mediates tissue-
protective effects of ARBs in obesity and metabolic syndrome.
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Although it has traditionally been con-
sidered a silent organ that passively stores 
excess energy, we now recognize adipose 
tissue as an important endocrine organ. 
Adipose tissue secretes a variety of bioac-
tive substances, which are called adipocy-
tokines, or adipokines. Of these adipokines, 
adiponectin has recently attracted much 
attention because of its antidiabetic eff ects. 
Two receptor forms have been cloned for 
adiponectin, AdipoR1, and AdipoR2. 
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These receptors contain seven-trans-
membrane domains. However, they are 
structurally and functionally distinct from 
traditional G protein-coupled receptors. 
Th us far, signal transduction of AdipoRs 
to stimulate insulin sensitization appears 
to involve activation of AMP-activated 
protein kinase (AMPK), p38 mitogen-
activated protein kinase, and peroxi-
some proliferator-activated receptor-α 
(PPARα).1 In addition to weight loss, an 
increase in adiponectin levels is observed 
after treatment with PPARγ-activating 
thiazolidinediones, which may be critical 
in their insulin sensitization. Although 
adiponectin is derived from adipose tissue, 
plasma concentration of adiponectin cor-
related negatively with a vast majority of 
risk factors, such as obesity, type 2 diabetes, 
glucocorticoids, testosterone, and hyper-
lipidemia. Moreover, recent studies suggest 
a strong link between cardiovascular dis-
eases and hypoadiponecinemia.1,2 In this 
regard, blockade of the renin–angiotensin 
system (RAS) appears to increase plasma 
adiponectin.3,4 Supporting this notion, 
angiotensin II (Ang II) infusion decreased 
plasma concentrations of adiponectin 
and adipose tissue levels of adiponectin 
mRNA.5 However, the molecular mecha-
nisms by which RAS inhibition stimulates 
adiponectin production remain unclear.
Kurata et al.6 (this issue) provide sig-
nificant insights into the molecular 
mechanism of RAS in adipokine regula-
tion.6 Th eir study demonstrates that ol-
mesartan, an Ang II type-1 (AT1) receptor 
blocker (ARB), inhibits obesity-induced 
hypoadiponectinemia. Olmesartan 
also ameliorates dysregulation of other 
adipokines, including tumor necrosis 
factor-α, plasminogen activator inhibi-
tor-1, serum amyloid A3, and monocyte 
chemotactic protein-1. Interestingly, 
the ARB also inhibits overexpression 
of reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) subunits 
and a transcriptional factor, PU.1 (which 
upregulates the transcription of NADPH 
oxidase subunits), in the obese tissue. In 
line with recent studies,7 reactive oxygen 
species (ROS) appear to reduce adiponec-
tin production in adipose tissue, which is 
inhibited by olmesartan. In addition to 
the inhibition of the AT1 receptor–ROS 
axis,6 there are two possible additional 
mechanisms by which ARB enhances 
adiponectin production (Figure 1). Some 
ARBs, including irbesartan and telmisar-
tan, have PPARγ-activating properties,8 
thereby stimulating adiponectin produc-
tion. Another mechanism is AT2 receptor 
activation in the absence of AT1 receptor 
activation. Such a phenomenon is sug-
gested by the fi nding that expression of 
PPARγ can be stimulated by AT2 recep-
tor activation in an AT1 receptor-defi cient 
cell model.8
In addition to its inhibitory eff ect on 
adiponectin production in adipocytes, 
the RAS also interacts with adiponectin 
in their target cells. Endothelial dysfunc-
tion, characterized as decreased nitric 
oxide (NO) bioavailability, is believed 
to be a key causal link between insulin 
resistance and cardiovascular diseases. In 
endothelial cells, adiponectin stimulates 
